A new study from researchers at Providence, published in Nature NPJ Genomic Medicine, demonstrates how Whole Genome Sequencing (WGS) can transform health care by enabling earlier disease detection, tailored prevention strategies, and more precise treatment decisions. As a pilot program for population sequencing within a large U.S. community health system, the Geno4ME study underscores the growing role of genomics in everyday medical care, particularly for communities who have historically lacked access.
In the paper titled "TRIALSCOPE — A Framework for Clinical Trial Simulation from Real-World Data," Providence and Microsoft researchers propose an innovative framework dubbed TRIALSCOPE to automate the generation of Real-World Evidence (RWE) from Electronic Medical Record (EMR) data. The model uses AI to organize unstructured patient data and then simulates clinical trials to estimate the effects of treatments. It also tests how changes in criteria for who can participate in clinical trials could impact trial outcomes, giving researchers another tool to shape more effective trials for specific patient populations.
New Providence research published in Nature-Precision Oncology finds that in head and neck cancer, researchers found that two specific immune response patterns—called Activation and Infiltration—can better predict who will benefit from immunotherapy. Patients whose tumors showed both patterns responded best to treatment and lived longer. These findings, confirmed in multiple patient groups, suggest that using combined biomarkers is more effective than relying on a single one.
A wide variety of medical imaging tools (CT,MRI, pathology etc.) are used in routine medical care, and represent robust datasets for potential biomedical discovery using Artificial Intelligence (AI).A huge challenge is that each of these imaging tools produce highly complex images, and algorithms developed for one imaging modality typically are inaccurate when applied to another imaging type. With recent break throughs, researchers at Providence, Microsoft and the University of Washington have published a new all-in-one tool called BiomedParse that jointly conducts segmentation, detection, and feature recognition across nine different medical imaging modalities. This work paves the way for cutting-edge multimodal biomedical discovery, e.g., research that can be performed across large datasets regardless of imaging type.
Research from a team led by Brian Piening, PhD, Program Director for Providence Genomics that included colleagues from across Providence as well as collaborators at Illumina and Microsoft demonstrated that a majority (67%) of patients tested with the ProvSeq-Solid Tumor Comprehensive Genomic Profiling (CPG) test were candidates for guideline-recommended precision cancer therapy and those treated with these therapies showed significant improvements in overall survival rate versus chemotherapy.
In less than a year, Prevention4ME has identified more than 2600 patients at high risk for cancer who are now being screened differently or receiving NCCN guideline-recommended genetic testing Prevention4ME has been piloted at multiple sites across the system and is continually expanding system-wide. The program includes a novel virtual screening tool, patient and provider support, education, and integrated test ordering/resulting workflow.
Providence Genomics and Providence-Swedish Cancer Institute have launched the PREVAIL study, “Providence Evaluation of Annual Cancer Screenings” to understand the ways that individuals with a genetic predisposition to cancer access innovative screening tools and how access may impact their choices and care.
This research highlights a new artificial intelligence model that Providence, Microsoft, and the University of Washington used to diagnose cancer. The open-access model called Prov-GigaPath was developed and used to analyze more than a billion tissue sample images from 30,000 patients.
This pig-to-human study utilized genomics technology to map out when rejection events happen. This is helping scientists to better understand the detailed molecular landscape following xenotransplantation to enable earlier interventions.
This innovative Artificial Intelligence (AI) technology involves the digitization of traditional glass slides which enables pathologists to access, analyze, and share high-resolution whole-slide images (WSI) of tissue specimens in a digital format.
This first publication of an ongoing study is using a novel genomics liquid biopsy test in a large cohort of patients with both DCIS and IBC to track breast cancer in the blood to understand the invasive progression of breast cancer tumors.
Pharmacogenomics (PGx) isbecoming a cornerstone of precision medicine due to variations in drug safetyand efficacy attributed to an individual’s genetic profile.
An estimated 90 percent of individuals with inherited cancer risk do not know they are at risk.Providence is evaluating new models for identifying patients eligible for hereditary cancer risk assessment and genetic testing.
Researchers at Providence,Microsoft, and the University of Washington partner to fight cancer using AI.The project, called Prov-GigaPath is an open-access AI model now being used inclinical applications.
Providence Genomics and EACRI researchers conducted a multi-year study of the impact of removing testing barriers to comprehensive genomic profiling (CGP) for patients with advanced cancers.
